Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

Purpose: We studied the safety and tolerability of telatinib, an orally available, small-molecule tyrosine kinase inhibitor of the vascular endothelial growth factor receptor (VEGFR-2/VEGFR-3), platelet-derived growth factor receptor β, and c-Kit in combination with capecitabine and irinotecan. Experimental Design: Telatinib twice daily continuously, irinotecan once every 3 weeks, and capecitabine oral twice daily on day 1 to 14 were administered in cycles of 21 days in escalating doses in successive cohorts. Toxicity was evaluated to conform to the Common Terminology Criteria for Adverse Events version 3.0. Pharmacokinetic and (circulating) endothelial (progenitor) cell measurements were done. Tumor efficacy was evaluated using the Response Evaluation Criteria in Solid Tumors. Results: Twenty-three patients were included in this phase I trial. Most frequently (>25%) reported adverse events of any grade were vomiting, nausea, fatigue, diarrhea, alopecia, and hand-foot syndrome. A silent myocardial infarction and two cases of decreased left ventricular ejection fraction were reported; both were reversible. Cardiac monitoring of the subsequent patients did not reveal other abnormalities. The study was terminated when the recommended single agent phase II doses of telatinib (900 mg twice daily) and capecitabine/irinotecan was reached. Pharmacokinetic profiles showed no clinically relevant changes upon coadministration of the three drugs. (Circulating) endothelial (progenitor) cell levels stabilized during treatment. Five of 23 patients had partial remission and 9 of 23 patients showed stable disease. Conclusions: Continuous administration of 900 mg telatinib twice daily can be safely combined with irinotecan (180 mg/m2) and capecitabine (1,000 mg/m2 twice daily, day 1-14) and is the recommended schedule for further phase II studies. Tumor shrinkage and disease stabilization was observed. Cardiac toxicity needs further investigation in following studies. Clin Cancer Res; 16(7); 2187–97. ©2010 AACR.

[1]  M. Fukuoka,et al.  Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non–small cell lung cancer , 2009, Investigational New Drugs.

[2]  J. Bloem,et al.  Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Hauschild,et al.  Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[5]  A. Ardavanis,et al.  Cardiotoxicity induced by tyrosine kinase inhibitors , 2009, Acta oncologica.

[6]  S. Paggi,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[7]  C. Zielinski,et al.  Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Ellis,et al.  Pathways Mediating Resistance to Vascular Endothelial Growth Factor–Targeted Therapy , 2008, Clinical Cancer Research.

[9]  R. Kerbel,et al.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. , 2008, Cancer cell.

[10]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[11]  D. Hanahan,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[12]  H. Putter,et al.  Hypertension and Rarefaction during Treatment with Telatinib, a Small Molecule Angiogenesis Inhibitor , 2008, Clinical Cancer Research.

[13]  A. Harris,et al.  A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors , 2008 .

[14]  I. Weissman,et al.  Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth , 2008, Proceedings of the National Academy of Sciences.

[15]  E. Voest,et al.  The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. , 2008, Current clinical pharmacology.

[16]  D. Nolan,et al.  Endothelial Progenitor Cells Control the Angiogenic Switch in Mouse Lung Metastasis , 2008, Science.

[17]  E. Perez,et al.  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. , 2007, The New England journal of medicine.

[18]  J. Christensen,et al.  Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy , 2007, Proceedings of the National Academy of Sciences.

[19]  H. Verheul,et al.  Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition , 2007, Nature Reviews Cancer.

[20]  Rakesh K Jain,et al.  A protocol for phenotypic detection and enumeration of circulating endothelial cells and circulating progenitor cells in human blood , 2007, Nature Protocols.

[21]  Ricky T. Tong,et al.  Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.

[22]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[23]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[24]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[25]  U. Vanhoefer,et al.  A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  D. Hicklin,et al.  Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors , 2006, Science.

[27]  E. Van Cutsem,et al.  Results of an interim analysis of a multinational randomized, double-blind, phase III study in patients (pts) with previously treated metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo (CONFIRM 2). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  G. Rosner,et al.  Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Kerbel.  Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer? , 2006, Science.

[30]  R. Jain,et al.  Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. , 2006, Blood.

[31]  K. Flaherty,et al.  Mechanisms of hypertension associated with BAY 43-9006. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[33]  D. Rea,et al.  A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  J. Hainsworth,et al.  A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1) , 2005 .

[35]  Rakesh K Jain,et al.  Antiangiogenic therapy for cancer: current and emerging concepts. , 2005, Oncology.

[36]  J. Pierga,et al.  A phase I clinical and pharmacokinetic study of capecitabine (Xeloda®) and irinotecan combination therapy (XELIRI) in patients with metastatic gastrointestinal tumours , 2005, British Journal of Cancer.

[37]  B. Peters,et al.  Contribution of bone marrow–derived endothelial cells to human tumor vasculature , 2005, Nature Medicine.

[38]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[39]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[40]  L. Mariani,et al.  Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma , 2004, Cancer.

[41]  W. Gerald,et al.  Effect of angiogenesis inhibition by Id loss and the contribution of bone-marrow-derived endothelial cells in spontaneous murine tumors. , 2003, Cancer cell.

[42]  S. Frings,et al.  Capecitabine and irinotecan as first-line chemotherapy in patients with metastatic colorectal cancer: results of an extended phase I study. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  S. Rafii,et al.  Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.

[44]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[45]  Takayuki Asahara,et al.  Isolation of Putative Progenitor Endothelial Cells for Angiogenesis , 1997, Science.

[46]  Daoyuan Wang,et al.  A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. , 2010, Japanese journal of clinical oncology.

[47]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[48]  Jeffrey W. Clark,et al.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer , 2006, Nature Clinical Practice Oncology.

[49]  E. Raymond,et al.  Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.